Premium
FIXED‐DURATION VENETOCLAX PLUS OBINUTUZUMAB IMPROVES PFS AND MINIMAL RESIDUAL DISEASE NEGATIVITY IN PATIENTS WITH PREVIOUSLY UNTREATED CLL AND COMORBIDITIES
Author(s) -
Fischer K.,
Porro Lurà M.,
AlSawaf O.,
Bahlo J.,
Fink A.,
Tandon M.,
Dixon M.,
Robrecht S.,
Warburton S.,
Humphrey K.,
Samoylova O.,
Liberati A.M.,
PinillaIbarz J.,
Opat S.,
Sivcheva L.,
Le Dû K.,
Fogliatto L.M.,
Utoft Niemann C.,
Weinkove R.,
Robinson S.,
Kipps T.J.,
Boettcher S.,
Tausch E.,
Schary W.L.,
Eichhorst B.,
Wendtner C.,
Langerak A.W.,
Kreuzer K.,
Goede V.,
Stilgenbauer S.,
Mobasher M.,
Ritgen M.,
Hallek M.
Publication year - 2019
Publication title -
hematological oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.52_2629
Subject(s) - medicine , gastroenterology , minimal residual disease , obinutuzumab , hazard ratio , clinical endpoint , population , surrogate endpoint , oncology , venetoclax , progression free survival , confidence interval , surgery , chronic lymphocytic leukemia , randomized controlled trial , bone marrow , leukemia , chemotherapy , environmental health